19:07:38 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-06-15 Årsstämma 2024
2024-05-17 Ordinarie utdelning ASAP 0.00 SEK
2024-02-27 Bokslutskommuniké 2023
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-23 Ordinarie utdelning ASAP 0.00 SEK
2023-05-22 Årsstämma 2023
2023-02-27 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-05 Ordinarie utdelning ASAP 0.00 SEK
2022-05-04 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 15-10 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-18 Kvartalsrapport 2021-Q1
2021-04-22 Ordinarie utdelning ASAP 0.00 SEK
2021-04-21 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-26 Kvartalsrapport 2020-Q1
2020-05-06 Ordinarie utdelning ASAP 0.00 SEK
2020-05-05 Årsstämma 2020
2020-02-21 Bokslutskommuniké 2019
2020-01-21 Extra Bolagsstämma 2019
2019-11-20 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-20 Kvartalsrapport 2019-Q1
2019-05-09 Ordinarie utdelning ASAP 0.00 SEK
2019-02-25 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Asarina Pharma är ett svenskt läkemedelsbolag med fokus på läkemedel för kvinnors hälsa. Bolagets huvudprodukt, som är under utveckling, är Sepranolone. Sepranolone är avsett för behandling av PMDD, den allvarligaste formen av Premenstruel stress (PMS). Verksamhet innehas runtom den nordiska marknaden. Asarina Pharma har sitt huvudkontor i Solna, Sverige.
2022-09-05 13:24:00
A new study by the U.S. CDC (Centers for Disease Control and Prevention) estimates that 1-in-50 children in the US may be affected by Tourette or persistent tic disorders, previous estimates were 1-in-100, and that up to 450,000 U.S. children and adults have Tourette. Asarina Pharma is currently carrying out a phase IIa clinical study into Sepranolone, an endogenous neurohormonal treatment for Tourette that aims to reduce tics with no significant side effects.

A new study – ‘Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States’ - has been published in the journal Psychiatry Research. The study was carried out by scientists from the Child Development and Disability Branch of the Division of Human Development and Disability at the Centers for Disease Control and Prevention in Atlanta USA.

The study suggests that Tourette and persistent tic disorders are significantly more prevalent than previously reported. It estimates that in total 1.4 million people in the US have Tourette or significant tic disorder, including 350,000 – 450,000 Tourette cases.

One key finding estimates that 1-in-50 children (5 – 14 yrs.) may be affected by the conditions - previous estimates were 1-in-100 (Tourette Association of America.) A previous CDC study (1) found that from 2016 to 2019 1-in-333 children aged between 3–17 yrs. in the U.S. received a Tourette diagnosis, and suggested that 50% of children with TS may not be diagnosed.

Asarina Pharma CEO Peter Nordkild: “These are interesting and important findings. They confirm expert opinion that Tourette is under-diagnosed and highly likely to be more prevalent than thought. I believe that the availability of a new, safer treatment would be likely to drive diagnosis and awareness, helping more parents and children find their way towards new treatment – and a new control over their lives.”

  1. Bitsko RH, Claussen AH, Lichstein J, et al. Mental Health Surveillance Among Children – United States, 2013 – 2019 MMWR Suppl. 2022;71(2):1-48.